BioNTech SE (NASDAQ:BNTX) trading with an addition of $10.96 to $247.10 on Thursday, an upside of 4.64 percent. An average of 3,176,018 shares of common stock have been traded in the last five days. There was a fall of -$28.30 in the past week. The last 20 days have seen an average of 3,428,715 shares traded, while the 50-day average volume stands at 4,564,686.
BNTX stock has decreased by -31.87% in the last month. The company shares reached their 1-month lowest point of $230.03 on 10/01/21. With the stock rallying to its 52-week high on 08/10/21, shares of the company touched a low of $75.35 and a high of $464.00 in 52 weeks. In spite of this, the price is down -46.75% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
BioNTech SE (BNTX) has a trailing price-to-earnings (P/E) ratio of 12.47, which compares with the 34.65 for the broader industry and 32.28 for the sector. This means investors are optimistic about the stock’s future prospects. In the last five years, BioNTech SE’s PE ratio has ranged between 749.25 and 10.77. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 6.82, the price-to-book (PB) ratio at 9.08.
The company has a payout ratio of 0.00%.
The quick ratio of BioNTech SE for the three months ended June 29 was 2.60, and the current ratio was 2.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.09 and a total debt to equity ratio of 0.22 for the quarter ending June 29. BioNTech SE’s EBITDA margin for the year ending June 29 is -47.24%, while its operating margin for the same period stands at 76.20%. Its gross profit as reported stood at $483.18 million compared to revenue of $550.96 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, BioNTech SE’s return on assets was 95.10%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, BioNTech SE had $1.01 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $540.2 million in the quarter, while revenues of $0.0 were grew 77.49%. The analyst consensus anticipated BioNTech SE’s latest quarter earnings to come in at $8.79 per share, but it turned out to be $12.49, a 42.10% surprise. For the quarter, EBITDA amounted to $5.08 billion.
From a technical analysis perspective, let’s take a brief look at BioNTech SE (BNTX) price momentum. RSI 9-day as of the close on 06 October was 26.58%, suggesting the stock is oversold, with historical volatility in this time frame at 63.70%.
As of today, BNTX’s price is $246.93 -10.37% or -$28.30 from its 5-day moving average. BNTX is currently trading -30.36% lower than its 20-day SMA and +23.39% higher than its 100-day SMA. However, the stock’s current price level is -21.94% below the SMA50 and +129.84% above the SMA200.
The stochastic %K and %D were 9.83% and 11.64%, respectively, and the average true range (ATR) was 20.52. With the 14-day stochastic at 11.28% and the average true range at 21.66, the RSI (14) stands at 32.01%. The stock has reached -19.54 on the 9-day MACD Oscillator while the 14-day reading was at -47.40.
Jefferies launched coverage on BioNTech SE (NASDAQ: BNTX) in its analyst report released on October 07, 2021. The firm assigned the stock a a Hold rating.The consensus rating for BioNTech SE (BNTX) among analysts is Hold. According to current brokerage recommendations, 1 brokerage firm advise that investors sell BNTX, while 8 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is BNTX’s price target for the next 12 months?
Analysts predict a range of price targets between $130.36 and $384.66, with a median target of $311.97. Taking a look at these predictions, the average price target given by analysts for BioNTech SE (BNTX) stock is $287.09.